Alterity Therapeutics (ATHE) Common Equity (2015 - 2025)

Alterity Therapeutics has reported Common Equity for 11 years, with the latest figure at $35.6 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity rose 599.79% year-over-year to $35.6 million; the trailing twelve-month figure through Dec 2025 stood at $35.6 million (up 599.79% YoY), and the FY2025 full-year result was $27.2 million, up 198.64% from the prior year.
• Common Equity for Q4 2025 stood at $35.6 million, up from $27.2 million in the prior quarter.
• The five-year high for Common Equity was $35.6 million in Q4 2025, with the low at $228129.1 in Q2 2023.
• Average Common Equity over 5 years is $19.0 million, with a median of $21.0 million recorded in 2021.
• Year-over-year, Common Equity tumbled 99.1% in 2023 and surged 5560.24% in 2024.
• Tracing ATHE's Common Equity over 5 years: stood at $30.0 million in 2021, then plunged by 38.37% to $18.5 million in 2022, then sank by 37.87% to $11.5 million in 2023, then plunged by 55.62% to $5.1 million in 2024, then surged by 599.79% to $35.6 million in 2025.
• The last three Common Equity figures came in at $35.6 million (Q4 2025), $27.2 million (Q2 2025), and $5.1 million (Q4 2024), per Business Quant data.

Peer Comparison